TYK’s EGFR Inhibitor Bests Tagrisso In NSCLC Brain Metastases
Top-Line iORR Findings Released
Chinese biotech TYK Medicines says its EGFR inhibitor outperformed AstraZeneca’s same-class blockbuster Tagrisso in a pivotal Phase II trial for first-line use in brain metastases resulting from EGFR mutation-positive non-small cell lung cancer.
